ReVision Optics

ReVision Optics raised $172 million to solve presbyopia, the age-related loss of eye focusing ability affecting over one billion people globally. ​​‌‌‌‌‌‌‌​‌‌​​‌​​​​​​‌‌​‌‌‌​​​‌‌The problem was acute for adults over 40 who struggled with reading and close-up tasks, and it was measurable through standard vision tests. Existing solutions included reading glasses, bifocals, contact lenses, and surgical procedures like LASIK modifications. ReVision developed corneal inlays—tiny devices implanted in the eye to restore near vision—positioning themselves as a less invasive alternative to surgery. The company's fundamental miscalculation was overestimating patient demand for an invasive procedure with uncertain long-term safety data. While presbyopia affected millions, most patients accepted glasses as a convenient, reversible solution. ReVision missed critical warning signs: limited patient enthusiasm during trials, modest reimbursement prospects, and the procedure's irreversibility deterring adoption. The company ultimately failed to achieve meaningful market penetration, demonstrating that solving a widespread problem doesn't guarantee commercial success when patients prefer simpler alternatives.

ReVision Optics raised $172M from top-tier VCs to commercialize corneal inlays—tiny devices implanted in the eye to correct presbyopia. Early signals looked promising: ophthalmologists expressed enthusiasm during product demonstrations, and the company secured FDA approval in 2015. However, the behavioral reality diverged sharply from stated interest. While doctors praised the technology, actual adoption remained sluggish. Patient uptake proved far lower than projected because the procedure cost $3,000-4,000 out-of-pocket, and many patients feared permanent eye surgery for a presbyopia solution. ReVision measured interest through physician surveys and clinical trial enrollment, but these metrics masked the critical gap between what doctors said they'd recommend and what patients actually chose. The warning sign was obvious in hindsight: no one was paying. Despite FDA clearance and physician endorsement, the company couldn't generate sustainable revenue. ReVision eventually pivoted and was acquired by Bausch + Lomb in 2017, having validated clinical efficacy but failed to validate genuine market demand at scale.